Patents & Public Health

Slides:

Advertisements

Similar presentations

Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,

Advertisements

Impact of JUSFTA on affordability and availability of medicines from perspective of local generic manufacturers Towards equitable and affordable medicine.

1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.

2 nd WIPO Inter-Regional Meeting on South- South Cooperation on Patents, Trademarks, Geographical Indications, Industrial Designs and Enforcement Cairo.

Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.

Thailand’s fight for national sovereignty - the issue of compulsory licenses Since coup Sept 2006, the new interim government issued compulsory licenses.

J.P. Singh Georgetown University Communication, Culture, & Technology Program TRIPS: Negotiating Intellectual Property in the World Trading System J.

The World Public Health at a Crossroad Guillermo Foladori CSPO Columbia University 2003 Meeting “The Uneven Evolution of Medical Know-how” Burden Room,

Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.

Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

Innovation: Indian Initiatives and Challenges Ahead R. Kumar Department of Chemical Engineering Indian Institute of Science Bangalore , India.

Medicine Access: Claims & Data Sanjay Basu. The Framework for Access The pipeline fallacy Patents and pricing.

Game Changers Radicalization of ART tools and delivery New ways to manage IP: aggressive use of TRIPS flex and effective patent pool Financial transaction.

Competition Assessment of the Indian Pharmaceuticals Sector Aditya Bhattacharjea Fiyanshu Sindhwani Centre for Development Economics, Delhi School of Economics.

THE PRICE OF LIFE: INTELLECTUAL PROPERTY, PATENTS AND STANDARDS IN GLOBAL HEALTH DR PHOEBE LI LECTURER, SUSSEX LAW SCHOOL UNIVERSITY OF SUSSEX 19/07/2013.

More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.

Access to Innovation: Making Generic Versions of Newer Antiretrovirals Affordable Focusing on middle income countries Leena Menghaney, MSF Access Camapign.

Intellectual Property Rights and Technology Transfer Keith E. Maskus WIPO-WTO Joint Workshop 17 November 2003.

Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,

Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani. by Shyama V. Ramani a And Augustin Maria b, Mahesh Ravi c, Preethi Pradhan d, a INRA,

Public health, innovation and intellectual property 1 |1 | Dr Germán Velásquez Director WHO Secretariat Public Health, Innovation and Intellectual Property.

Procurement of patented and other essential medicines: challenges and opportunities Wilbert Bannenberg, MD MPH Zambia TRIPS workshop.

Colin McInnes Simon Rushton Owain Williams. From NHS to ‘Global Health’

1 Patents and Public Health Dr. Eric Noehrenberg Director International Trade and Market Policy, IFPMA WIPO Open Forum on the draft SPLT, Geneva, 3 March.

International IP Regime and A2M : Role of BRICS K M Gopakumar TWN.

D OHA N EGOTIATIONS & I NDIA P resenters * E vgeniya Burova * M ohini Patel.

Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?

monopolisation of $ € € D  In 1985 global seed trade totalled 18 bn $ The four highest ranking companies covered 8 % of the market  In 2006 global seed.

WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,

Global Patent Debate K.Ravi Srinivas May 12-13, 2011.

UNCTAD/CD-TFT 1 Intellectual Property Rights and National Development Goals – Ensuring Innovation in Russia St. Petersburg/Moscow Study Tour 2008 Christoph.

WTO, TRIPS, PATENT RULES & DEVELOPING COUNTRIES   Links Introduction Patent Effects Patent Effects Patent Effects Patent Effects Medicines Suggestions.

Incentives for Innovation (Push and Pull) Andrew Alexandra Director Australian Research Council Special Research Centre for Applied Philosophy and Public.

Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.

Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?

DIS 605 BY DOROBIN AGOTI REG NO: D61/71443/2008 ICT INNOVATION, LEGAL AND PIRACY ISSUES.

Presentation to Civil Society meeting Harare 21 January 2014.

Exploring New paradigms for Health R&D Dr Shaidah Asmall October 2007.

TRIPS TRIPS is the Agreement on Trade Related Aspects of Intellectual Property Rights Framed within the WTO, by “consensus” Regulates intellectual property.

PATENT POOL & its CONCERNS PATENT POOL & its CONCERNS Manmohan A Amonkar 20 July 2010.

‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.

Ellen ‘t Hoen Médecins sans Frontières

Access to Medicines Making Innovation work for the poor Corinna Heineke Diversity in Innovation European Patent Conference, Brussels, 15/16 May 2007.

Implementation of TRIPS Flexibilities In National IP Legislation For Strengthening Access To Medicines In Swaziland Workshop with MOH and stakeholders,

Access to medicines Elizabeth Holzer, Legal Policy Advisor A global and local - legal and health systems issues.

Maintaining Free Trade Among Nations. Overview You already know that international trade is important to all nations, even a country as large as the Canada.

Trade & Access to Medicines in India Centre for Trade & Development

TRIPS-Plus Pressures: Trade Agreements, and New Trade Policy Prof. Brook K. Baker OSI Kiev – IPRs & A2M, Sept. 16, 2009.

The Inequals of Uruguay Srividhya Ragavan University of Oklahoma College of Law.

Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.

AIDS DRUGS, NATIONAL EMERGENCY & CIPRO Srividhya Ragavan Nat. Academy For Legal Studies & Research.

WTO and SDGs: Issues before the Nairobi Ministerial TPP, TRIPS and Access to Medicines November 2015 Reji K. Joseph Associate Professor Institute.

NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.

Moving towards a Patent Pool? XVII International AIDS Conference Satellite Forum, MSF, KEI, OXFAM (Mexico, 5 August 2008) Jorge Bermudez Executive-Secretary,

Intellectual Property Protection and Access to Medicines

WTO, TRIPS, PATENT RULES & DEVELOPING COUNTRIES

Figure 4 Trend of patents granted by USPTO and IPO to the 123 sample firms by year of application, over the years 1999–2009. From: With the help of a foreign.

Carnegie Institution of Washington

Module: Seed Intellectual Property -Explains why Seed IP is a necessary protection for plant breeders to enable them to develop improved seed to help solve.

Thailand Development research Institute

Policy Policy Consistency ….. ….. Complementarity

Emerging Projects Day in One Health Final program

Big Oil, Big Prices FTE.

Intellectual Property Rights in Global Markets

Obligation to contribute to R&D costs Use of pharmaceutical inventions without authorization of patent owners James Love. CPTech 16 April 2004 Twelfth.

Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.

UF can do its part to close the access-to-medicines gap

Prof. Kiran Kalia, Director NIPER Ahmedabad

Presentation transcript:

Patents & Public Health IPR & the Pharma Sector Dr. Akun Sabharwal

Patents Act 1970 ‘’Process V/s Product’’ Patent The Effect Cost of medicine – Affordable Public Health Issues Social Justice Indian Pharma Industry: Became a Global Player Provided many in the developing world Dr. Akun Sabharwal

The new Patent Regime WTO, TRIPS… Product patent Linkage between Trade & IPR – Is it so? Trade – Liberalization of flow of goods & Services TRIPS – Imposes Trade-restrictive policies Medicine…Monopoly…Malice Dr. Akun Sabharwal

IPR & Innovation… Yes…Really? What about Evergreening Even if in small measure – Innovation goals to be traded off against health & lives lost from increased prices Dr. Akun Sabharwal

The Solution Compulsory Licensing for Life saving or essential medicines. Resist pressure to join or align policies with new trade agreements. Consolidation of approach to Pharma access & innovation - Prize Money Concept Support Pharma R&D Open Science Networks Dr. Akun Sabharwal